Neue Aspekte in der Therapie von Schilddrüsenkarzinomen
Standard
Neue Aspekte in der Therapie von Schilddrüsenkarzinomen : Highlights vom ASCO-Kongress 2018. / Möckelmann, N; Münscher, A.
in: HNO, Jahrgang 66, Nr. 12, 12.2018, S. 896-900.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Neue Aspekte in der Therapie von Schilddrüsenkarzinomen
T2 - Highlights vom ASCO-Kongress 2018
AU - Möckelmann, N
AU - Münscher, A
PY - 2018/12
Y1 - 2018/12
N2 - Whereas surgical treatment of thyroid carcinoma plays an important role especially in the early stages, a multimodal approach is pursued in the palliative setting, which, in addition to classical chemotherapy primarily involves treatment with tyrosine kinase inhibitors. An analysis of clinical trials and studies presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 is presented. In particular, studies on the treatment of radioiodine-refractory differentiated thyroid cancer, anaplastic thyroid cancer and immunotherapy were selected and analyzed. Clinically and preclinically relevant studies are presented and critically interpreted in this review.
AB - Whereas surgical treatment of thyroid carcinoma plays an important role especially in the early stages, a multimodal approach is pursued in the palliative setting, which, in addition to classical chemotherapy primarily involves treatment with tyrosine kinase inhibitors. An analysis of clinical trials and studies presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 is presented. In particular, studies on the treatment of radioiodine-refractory differentiated thyroid cancer, anaplastic thyroid cancer and immunotherapy were selected and analyzed. Clinically and preclinically relevant studies are presented and critically interpreted in this review.
KW - Humans
KW - Immunologic Factors
KW - Immunotherapy
KW - Iodine Radioisotopes/therapeutic use
KW - Thyroid Neoplasms/therapy
U2 - 10.1007/s00106-018-0589-z
DO - 10.1007/s00106-018-0589-z
M3 - SCORING: Review
C2 - 30402812
VL - 66
SP - 896
EP - 900
JO - HNO
JF - HNO
SN - 0017-6192
IS - 12
ER -